Genertec Universal Medical Group Company Limited
2666.HK
Hong Kong Stock Exchange4.57
HKD
- -
- -
Genertec Universal Medical Group Company Limited
2666.HK
(Hong Kong Stock Exchange)
Recent
price
4.57
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genertec Universal Medical Group Company Limited engages in financing, advisory, and medical services primarily within the People's Republic of China. It operates through two main business segments: Finance Business and Healthcare Business. The Finance Business segment offers direct finance leasing, sale and leaseback, accounts receivable factoring, operating leases, and advisory services. The Healthcare Business segment encompasses medical and healthcare services, hospital operations, import, export, and domestic trading of medical-related goods, equipment life cycle management, medical digitalization services, intelligent medical health and elder care, medical technology services, hospital construction and management, medical consulting, software development, and elderly care services. The company serves patients, hospitals, medical equipment suppliers, and public institutions, operating across various regions in China. Founded in 1984 and headquartered in Beijing, it operates as a subsidiary of China General Technology (Group) Holding Co., Ltd. In recent developments, Genertec Universal Medical Group has actively expanded its healthcare footprint through acquisitions, including completing the acquisition of five hemodialysis centers of Hainan Kangprui Hospital Management Co., Ltd, enhancing its nephrology specialty services. The company also acquired a controlling stake in ShanDong JB Soft & Info Technology Co., Ltd and has been advancing acquisitions in specialized medical institutions such as ophthalmology and oncology centers. Additionally, in 2023, it completed the controlling acquisition of Kaisi Xuanda Medical Technology Co., Ltd. Strategically, it signed cooperation agreements with financial institutions such as ICBC and CITIC Bank to launch specialized M&A loan businesses, strengthening its financial service offerings. Genertec Universal Medical is focused on refining operational management, promoting integrated medical services, and expanding specialized diagnosis and treatment capabilities, particularly in chronic kidney disease management and elderly care. The company has actively participated in China's Healthy China Initiative, developing a comprehensive health ecosystem that integrates disease prevention, medical treatment, rehabilitation, and elderly care. It has also established a healthcare and elderly care platform to address the aging population's needs, supporting community-level medical services via its network of clinics. These efforts are accompanied by medical digitalization and technology-driven healthcare solutions aimed at improving service quality and operational efficiency. Genertec Universal Medical Group's strategic moves in acquisitions, partnerships, and service diversification reflect its intent to broaden its medical service scope and solidify its position as a leading integrated medical and healthcare service provider in China. Genertec Universal Medical Group was formerly known as Universal Medical Financial & Technical Advisory Services Company Limited until it rebranded in 2018. Its ongoing operational enhancements, acquisitions of specialty hospitals and medical technology firms, and expansion of healthcare services showcase a strategic shift toward comprehensive medical and elderly care services aligned with national healthcare policies and demographic trends. The company continues to leverage its position as a central enterprise medical group and is headquartered in Beijing, operating extensively in China with a broad portfolio of healthcare and financial service products designed to serve institutional and individual clients across the healthcare ecosystem. All information is accurate as of late 2025.